Neuroscience

Cumulus Neuroscience to Partner with The Digital Medicine Society (DiMe) to Drive Adoption of Digital Endpoints in Clinical Trials

Cumulus to participate in The Digital Health Measurement Collaborative Community (DATAcc) by DiMe project – Building the Business Case for…

1 month ago

Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001

With Growing Body of Clinical Evidence, ALX-001 is Ready to Commence Phase 2 StudiesNEW HAVEN, Conn., June 11, 2024 (GLOBE…

1 month ago

Cutera® Appoints Jeryl L. Hilleman to Board of Directors

Experienced Healthcare Executive Brings Extensive Financial and Operational Expertise to Cutera Board of DirectorsBRISBANE, Calif.--(BUSINESS WIRE)--CUTERA, INC. (Nasdaq: CUTR), a…

1 month ago

Cala TAPS Therapy is Now Covered by Medicare for Essential Tremor Patients, And Company Appoints CEO and President

SAN MATEO, Calif., June 10, 2024 /PRNewswire/ -- Cala, the bioelectronic medicine leader, reached a major milestone: a positive Medicare…

1 month ago

Bye, Bye Brain Fog: Zurge’s Proprietary Coffee Blend Sharpens Memory and Increases Mental Clarity

Formulated with breakthrough ingredient CognatiQ, this all-natural coffee is like no other Irving, TX – Zurvita is changing the morning…

1 month ago

NextSense Honored as World Economic Forum Technology Pioneer

MOUNTAIN VIEW, Calif., June 6, 2024 /PRNewswire/ -- NextSense is proud to announce that it has been recognized as a…

1 month ago

Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer   

Josep Catllà EVP, Chief Corporate Affairs Officer PARIS, FRANCE, 06 June 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global…

1 month ago

QuantalX Partners with the University of Illinois Chicago, Towards Successful US Commercialization

NEW YORK, June 5, 2024 /PRNewswire/ -- QuantalX Neuroscience Ltd, a pioneering medical technology company, is delighted to announce its…

1 month ago

Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs

- Company positioning multiple assets for late-stage development across its therapeutic pipeline – BOSTON and ATLANTA, June 05, 2024 (GLOBE…

1 month ago

Ocular Therapeutix® to Host Investor Day on June 13, 2024

Company to highlight corporate strategy, clinical data, and development plans for AXPAXLI™ in wet AMD and NPDR Event to feature prominent…

1 month ago